⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of IDEAYA Biosciences and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
IDEAYA Biosciences
↗South San Francisco, USA
IDEAYA Biosciences is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company specializes in synthetic lethality and antibody-drug conjugates (ADCs) to address hard-to-treat cancers, integrating small-molecule drug discovery with translational biomarker validation.
Headquartered in South San Francisco, IDEAYA is publicly traded and maintains a deep clinical-stage pipeline. Its lead program, darovasertib, is a protein kinase C (PKC) inhibitor currently in late-stage clinical development for uveal melanoma, with significant recent positive data from registrational trials.
CLASSIFICATION
SIZE & FINANCIALS
Employees:101-500
Founded:2015
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Investors:5AM Ventures, Canaan Partners
STOCK
Exchange:NASDAQ
Ticker:IDYA
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (Darovasertib)
Modalities:Small molecule, Antibody-drug conjugate (ADC), Bispecific ADC
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Servier (Darovasertib licensing), Roche (IDE892 collaboration), AstraZeneca (IDE849 collaboration), GlaxoSmithKline, Pfizer, Gilead Sciences
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Yujiro S. Hata - CEO
Theodora Ross - Chief Development Officer
Michael White - Chief Scientific Officer
LINKS
Website:ideayabio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with IDEAYA Biosciences. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.